Wall Street brokerages predict that Horizon Therapeutics PLC (NASDAQ:HZNP) will post sales of $299.66 million for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Horizon Therapeutics’ earnings. The highest sales estimate is $301.90 million and the lowest is $296.83 million. Horizon Therapeutics reported sales of $302.84 million in the same quarter last year, which would indicate a negative year over year growth rate of 1.1%. The firm is expected to report its next earnings report on Wednesday, August 14th.
According to Zacks, analysts expect that Horizon Therapeutics will report full year sales of $1.27 billion for the current financial year, with estimates ranging from $1.26 billion to $1.27 billion. For the next year, analysts anticipate that the firm will report sales of $1.40 billion, with estimates ranging from $1.36 billion to $1.42 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that that provide coverage for Horizon Therapeutics.
Horizon Therapeutics (NASDAQ:HZNP) last issued its earnings results on Wednesday, May 8th. The biopharmaceutical company reported $0.30 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.10 by $0.20. Horizon Therapeutics had a return on equity of 33.57% and a net margin of 3.79%. The business had revenue of $280.00 million during the quarter, compared to analyst estimates of $238.35 million. During the same quarter in the previous year, the firm earned $0.03 EPS. Horizon Therapeutics’s revenue was up 25.0% on a year-over-year basis.
A number of equities analysts have weighed in on HZNP shares. Citigroup boosted their target price on Martin Marietta Materials from $239.00 to $255.00 and gave the stock a “buy” rating in a research report on Wednesday, May 1st. BidaskClub lowered shares of Virtu Financial from a “sell” rating to a “strong sell” rating in a research report on Wednesday, June 12th. Cantor Fitzgerald upped their price target on shares of Horizon Therapeutics from $26.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, April 2nd. TheStreet lowered shares of Worthington Industries from a “b-” rating to a “c+” rating in a research report on Monday, June 10th. Finally, BMO Capital Markets set a $13.00 price target on shares of Vale and gave the company a “hold” rating in a research report on Thursday, April 4th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $31.91.
In related news, EVP Vikram Karnani sold 13,111 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $25.02, for a total transaction of $328,037.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jeff Kent sold 3,620 shares of the business’s stock in a transaction that occurred on Wednesday, June 5th. The shares were sold at an average price of $24.64, for a total value of $89,196.80. The disclosure for this sale can be found here. Insiders own 4.10% of the company’s stock.
Several large investors have recently made changes to their positions in the stock. Calamos Advisors LLC grew its stake in shares of Horizon Therapeutics by 3.1% during the 1st quarter. Calamos Advisors LLC now owns 13,400 shares of the biopharmaceutical company’s stock valued at $354,000 after acquiring an additional 400 shares during the period. Creative Planning boosted its stake in Horizon Therapeutics by 3.2% in the 1st quarter. Creative Planning now owns 16,290 shares of the biopharmaceutical company’s stock worth $431,000 after purchasing an additional 500 shares during the period. American International Group Inc. boosted its stake in Horizon Therapeutics by 0.8% in the 4th quarter. American International Group Inc. now owns 110,573 shares of the biopharmaceutical company’s stock worth $2,161,000 after purchasing an additional 868 shares during the period. Jabodon PT Co. boosted its stake in Horizon Therapeutics by 0.8% in the 1st quarter. Jabodon PT Co. now owns 114,687 shares of the biopharmaceutical company’s stock worth $3,031,000 after purchasing an additional 895 shares during the period. Finally, Intrust Bank NA boosted its stake in Horizon Therapeutics by 6.9% in the 1st quarter. Intrust Bank NA now owns 15,666 shares of the biopharmaceutical company’s stock worth $414,000 after purchasing an additional 1,008 shares during the period. Institutional investors own 87.79% of the company’s stock.
Shares of NASDAQ:HZNP opened at $23.46 on Thursday. Horizon Therapeutics has a fifty-two week low of $16.56 and a fifty-two week high of $29.44. The stock has a 50-day simple moving average of $23.99. The company has a current ratio of 1.74, a quick ratio of 1.68 and a debt-to-equity ratio of 0.90. The stock has a market cap of $4.34 billion, a price-to-earnings ratio of 12.82, a price-to-earnings-growth ratio of 1.35 and a beta of 1.03.
About Horizon Therapeutics
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Recommended Story: The risks of owning bonds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.